We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+5.92%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$483M
AUM Growth
+$65.3M
Cap. Flow
+$58.7M
Cap. Flow %
12.16%
Top 10 Hldgs %
61.19%
Holding
32
New
12
Increased
7
Reduced
8
Closed
4

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$39.6M
2
BMY icon
Bristol-Myers Squibb
BMY
+$19.9M
3
IDXX icon
Idexx Laboratories
IDXX
+$19.7M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$19.1M
5
UNH icon
UnitedHealth
UNH
+$16M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$50.2M
2
PCVX icon
Vaxcyte
PCVX
+$31.1M
3
UTHR icon
United Therapeutics
UTHR
+$19.7M
4
NTRA icon
Natera
NTRA
+$16.7M
5
STVN icon
Stevanato
STVN
+$15M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
1
Teva Pharmaceuticals
TEVA
$37.3B
$53.4M 11.06%
2,423,116
-332,621
-12% -$6.05M
ZBH icon
2
Zimmer Biomet
ZBH
$17.6B
$39M 8.07%
+369,004
New +$39.6M
ARGX icon
3
argenx
ARGX
$53.8B
$35.8M 7.42%
58,258
-4,216
-7% -$2.47M
NTRA icon
4
Natera
NTRA
$38.9B
$32.1M 6.65%
202,646
-114,793
-36% -$16.7M
INSP icon
5
Inspire Medical Systems
INSP
$1.46B
$28M 5.79%
150,788
-641
-0.4% -$124K
STVN icon
6
Stevanato
STVN
$5.23B
$24.4M 5.06%
1,121,804
-746,134
-40% -$15M
AXSM icon
7
Axsome Therapeutics
AXSM
$11.8B
$21.1M 4.38%
249,769
+158,048
+172% +$14.5M
VRNA
8
DELISTED
Verona Pharma
VRNA
$21.1M 4.37%
454,201
-139,779
-24% -$5.25M
AVDL
9
DELISTED
Avadel Pharmaceuticals
AVDL
$20.4M 4.22%
1,937,984
+277,029
+17% +$3.36M
BMY icon
10
Bristol-Myers Squibb
BMY
$124B
$20.1M 4.16%
+355,366
New +$19.9M
JAZZ icon
11
Jazz Pharmaceuticals
JAZZ
$15.5B
$19.9M 4.13%
+161,812
New +$19.1M
IDXX icon
12
Idexx Laboratories
IDXX
$44.8B
$18.6M 3.85%
+44,972
New +$19.7M
NVO
13
Novo Nordisk
NVO
$223B
$18.1M 3.74%
209,984
+142,727
+212% +$15.4M
MDGL icon
14
Madrigal Pharmaceuticals
MDGL
$12.8B
$14.6M 3.03%
47,472
+4,185
+10% +$1.18M
MRUS
15
DELISTED
Merus
MRUS
$14.6M 3.03%
347,303
+155,146
+81% +$7.45M
UNH icon
16
UnitedHealth
UNH
$387B
$14.2M 2.95%
+28,115
New +$16M
JANX icon
17
Janux Therapeutics
JANX
$992M
$12.7M 2.62%
+236,407
New +$12.5M
LEGN icon
18
Legend Biotech
LEGN
$4.31B
$12.6M 2.62%
388,704
+26,434
+7% +$1.09M
CI icon
19
Cigna
CI
$74.5B
$11.3M 2.33%
+40,810
New +$13M
WGS icon
20
GeneDx Holdings
WGS
$1.88B
$9.8M 2.03%
+127,567
New +$8.91M
GERN icon
21
Geron
GERN
$924M
$8.75M 1.81%
+2,472,836
New +$9.88M
EOLS icon
22
Evolus
EOLS
$377M
$8.2M 1.7%
+742,574
New +$10.4M
DFTX
23
Definium Therapeutics
DFTX
$5.88B
$5.71M 1.18%
820,793
-842,160
-51% -$5.79M
KRRO icon
24
Korro Bio
KRRO
$177M
$5.49M 1.14%
144,216
+80,202
+125% +$4.12M
BHVN icon
25
Biohaven
BHVN
$2.32B
$5.24M 1.08%
140,220
-52,975
-27% -$2.47M
1
2

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
LS
Leelyn Smith Geneva, Illinois $713M AUM 17.46% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return

Tri Locum Partners's Q4 2024 Portfolio in Review

As of Q4 2024, Tri Locum Partners held 32 positions worth $483M, up 16% from $417M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Tri Locum Partners deployed $58.7M of net new capital in Q4 2024, opening 12 new positions and adding to 7 existing holdings. Its largest new stake was Zimmer Biomet: 369,004 shares worth $39M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Natera, an estimated $16.7M trimmed.

  • Tri Locum Partners's largest Q4 2024 buy was Zimmer Biomet: 369,004 shares worth $39M.
  • Tri Locum Partners added most to Novo Nordisk in Q4 2024, an estimated $15.4M increase.
  • Tri Locum Partners's biggest Q4 2024 reduction was Natera, cutting an estimated $16.7M.
  • Tri Locum Partners fully exited Pfizer in Q4 2024, selling an estimated $50.2M.
  • Tri Locum Partners's ten largest holdings make up 61% of its $483M portfolio in Q4 2024.
  • Tri Locum Partners opened 12 new positions and closed 4 in Q4 2024.
  • Tri Locum Partners's portfolio value rose 16% quarter-over-quarter to $483M.

Based on Tri Locum Partners's 13F filing for Q4 2024, filed 14 Feb 2025.